WO2004016604A3 - Azabicyclic compounds are central nervous system active agents - Google Patents

Azabicyclic compounds are central nervous system active agents Download PDF

Info

Publication number
WO2004016604A3
WO2004016604A3 PCT/US2003/025471 US0325471W WO2004016604A3 WO 2004016604 A3 WO2004016604 A3 WO 2004016604A3 US 0325471 W US0325471 W US 0325471W WO 2004016604 A3 WO2004016604 A3 WO 2004016604A3
Authority
WO
WIPO (PCT)
Prior art keywords
active agents
nervous system
central nervous
system active
azabicyclic compounds
Prior art date
Application number
PCT/US2003/025471
Other languages
French (fr)
Other versions
WO2004016604A2 (en
Inventor
Michael J Dart
Xenia B Searle
Karin R Tietje
Richard B Toupence
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/219,223 external-priority patent/US20040044029A1/en
Priority claimed from US10/638,381 external-priority patent/US7135484B2/en
Application filed by Abbott Lab filed Critical Abbott Lab
Priority to MXPA05001726A priority Critical patent/MXPA05001726A/en
Priority to CA002495589A priority patent/CA2495589A1/en
Priority to EP03770235A priority patent/EP1539733A2/en
Priority to JP2005502054A priority patent/JP4629576B2/en
Publication of WO2004016604A2 publication Critical patent/WO2004016604A2/en
Publication of WO2004016604A3 publication Critical patent/WO2004016604A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

Compounds of formula (I), are novel CNS active agents that are useful for treating pain and for treating other disorders associated with the cholinergic system.
PCT/US2003/025471 2002-08-14 2003-08-13 Azabicyclic compounds are central nervous system active agents WO2004016604A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MXPA05001726A MXPA05001726A (en) 2002-08-14 2003-08-13 Azabicyclic compounds are central nervous system active agents.
CA002495589A CA2495589A1 (en) 2002-08-14 2003-08-13 Azabicyclic compounds are central nervous system active agents
EP03770235A EP1539733A2 (en) 2002-08-14 2003-08-13 Azabicyclic compounds are central nervous system active agents
JP2005502054A JP4629576B2 (en) 2002-08-14 2003-08-13 Azabicyclo compounds as central nervous system active agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/219,223 US20040044029A1 (en) 2002-08-14 2002-08-14 Azabicyclic compounds are central nervous system active agents
US10/219,223 2002-08-14
US10/638,381 US7135484B2 (en) 2002-08-14 2003-08-12 Azabicyclic compounds are central nervous system active agents
US10/638,381 2003-08-12

Publications (2)

Publication Number Publication Date
WO2004016604A2 WO2004016604A2 (en) 2004-02-26
WO2004016604A3 true WO2004016604A3 (en) 2004-04-08

Family

ID=32044938

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/025471 WO2004016604A2 (en) 2002-08-14 2003-08-13 Azabicyclic compounds are central nervous system active agents

Country Status (4)

Country Link
JP (1) JP4629576B2 (en)
CA (1) CA2495589A1 (en)
MX (1) MXPA05001726A (en)
WO (1) WO2004016604A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE451368T1 (en) 2003-10-15 2009-12-15 Targacept Inc AZABICYCLIC COMPOUNDS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISEASES
TW200845977A (en) 2007-03-30 2008-12-01 Targacept Inc Sub-type selective azabicycloalkane derivatives
CN103242216A (en) * 2013-05-07 2013-08-14 兰州梦唐精细化工有限公司 Synthesis method of N-Boc-hexahydro-5-oxo-cyclopenta (C) pyrrole
WO2020239073A1 (en) * 2019-05-30 2020-12-03 中国科学院上海药物研究所 Fused ring compound, preparation method therefor and use thereof

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0233793A2 (en) * 1986-01-13 1987-08-26 Roussel-Uclaf Decahydroquinoline derivatives, process for their preparation, intermediates for their preparation, their use as medicaments and compositions containing them
EP0612741A1 (en) * 1993-02-22 1994-08-31 Dr. Karl Thomae GmbH Cyclic derivatives, medicaments containing them and process for their preparation
WO1994022823A1 (en) * 1993-03-26 1994-10-13 Ortho Pharmaceutical Corporation 4-arylisoindole analgesics
WO1995015312A1 (en) * 1993-12-04 1995-06-08 Basf Aktiengesellschaft N-substituted azabicycloheptane derivatives used, for example, as neuroleptics
WO1995017384A1 (en) * 1993-12-23 1995-06-29 Ortho Pharmaceutical Corporation 4-arylisoindole analgesics
EP0899261A1 (en) * 1997-08-18 1999-03-03 Pfizer Inc. Optical active 1,4-dihydropyridine compounds as bradykinin antagonists
US5929087A (en) * 1997-04-08 1999-07-27 Regents Of The University Of Minnesota Decahydroquinoline-based anti-cholinergic agents
WO2002014319A2 (en) * 2000-08-11 2002-02-21 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
JP2002193964A (en) * 2000-12-22 2002-07-10 Sumitomo Pharmaceut Co Ltd Pyrazole derivative and its use in medicine
US20020094989A1 (en) * 2000-10-11 2002-07-18 Hale Jeffrey J. Pyrrolidine modulators of CCR5 chemokine receptor activity
WO2002085890A1 (en) * 2001-04-20 2002-10-31 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
WO2003004493A1 (en) * 2001-07-06 2003-01-16 Neurosearch A/S Novel compounds, their preparation and use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4341403A1 (en) * 1993-12-04 1995-06-08 Basf Ag N-substituted 3-azabicycloalkane derivatives, their preparation and use
US5541217A (en) * 1995-05-17 1996-07-30 Ortho Pharmaceutical Corporation 4-arylcyclopenta[c]pyrrole analgesics

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0233793A2 (en) * 1986-01-13 1987-08-26 Roussel-Uclaf Decahydroquinoline derivatives, process for their preparation, intermediates for their preparation, their use as medicaments and compositions containing them
EP0612741A1 (en) * 1993-02-22 1994-08-31 Dr. Karl Thomae GmbH Cyclic derivatives, medicaments containing them and process for their preparation
WO1994022823A1 (en) * 1993-03-26 1994-10-13 Ortho Pharmaceutical Corporation 4-arylisoindole analgesics
WO1995015312A1 (en) * 1993-12-04 1995-06-08 Basf Aktiengesellschaft N-substituted azabicycloheptane derivatives used, for example, as neuroleptics
WO1995017384A1 (en) * 1993-12-23 1995-06-29 Ortho Pharmaceutical Corporation 4-arylisoindole analgesics
US5929087A (en) * 1997-04-08 1999-07-27 Regents Of The University Of Minnesota Decahydroquinoline-based anti-cholinergic agents
EP0899261A1 (en) * 1997-08-18 1999-03-03 Pfizer Inc. Optical active 1,4-dihydropyridine compounds as bradykinin antagonists
WO2002014319A2 (en) * 2000-08-11 2002-02-21 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
US20020094989A1 (en) * 2000-10-11 2002-07-18 Hale Jeffrey J. Pyrrolidine modulators of CCR5 chemokine receptor activity
JP2002193964A (en) * 2000-12-22 2002-07-10 Sumitomo Pharmaceut Co Ltd Pyrazole derivative and its use in medicine
WO2002085890A1 (en) * 2001-04-20 2002-10-31 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
EP1386920A1 (en) * 2001-04-20 2004-02-04 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
WO2003004493A1 (en) * 2001-07-06 2003-01-16 Neurosearch A/S Novel compounds, their preparation and use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NAKATSUKA, MASASHI ET AL: "Pyrazoles and pharmaceutical compositions containing them for treatment of autoimmune diseases", XP002270028, retrieved from STN Database accession no. 137:88445 *
EFANGE ET AL: "Hydroxylated decahydroquinolines as ligands for the vesicular acetylcholine transporter: synthesis and biological evaluation", JOURNAL OF MEDICINAL CHEMISTRY., vol. 42, no. 15, 1999, AMERICAN CHEMICAL SOCIETY. WASHINGTON., US, pages 2862 - 2869, XP002270026, ISSN: 0022-2623 *
KROW G R ET AL: "Synthesis of 5- and 6-(6-Chloro-3-pyridyl)-2-azabicyclo[2.2.0]hexanes. Epibatidine Analogs", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 56, no. 47, 17 November 2000 (2000-11-17), pages 9233 - 9239, XP004238580, ISSN: 0040-4020 *
MARTIN ,S.F. ET AL: "Intramolecular[4+2]cycloadditions as a general strategy for alkaloid synthesis. A novel formal synthesis of lycorine", JOURNAL OF ORGANIC CHEMISTRY., vol. 47, no. 19, 1982, AMERICAN CHEMICAL SOCIETY. EASTON., US, pages 3634 - 3643, XP002270027, ISSN: 0022-3263 *

Also Published As

Publication number Publication date
MXPA05001726A (en) 2005-05-27
JP4629576B2 (en) 2011-02-09
WO2004016604A2 (en) 2004-02-26
JP2006513256A (en) 2006-04-20
CA2495589A1 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
AU2002220715A1 (en) Indolsulfonyl compounds useful in the treatment of cns disorders
EP1990338A3 (en) Biphenylcyclopropylamides as p-38 Kinase inhibitors
WO2003057698A3 (en) Spiroazacyclic compounds as monoamine receptor modulators
PL315193A1 (en) Diazabicyclic antagonists of neurokinin
MY124786A (en) Bis-arylsulfones
IL142768A0 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2003249983A1 (en) Piperidines useful for the treatment of central nervous system disorders
WO2004054501A3 (en) Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
YU63202A (en) 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
MXPA02012712A (en) N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity.
ZA200005217B (en) α-sulfonylamino hydroxamic acid inhibitors of matrix metalloproteinases for the treatment of peripheral or central nervous system disorders.
NZ544591A (en) Pyrrolodihydroisoquinolines as PDE10 inhibitors
ZA955868B (en) Substituted pyrimidine compounds and the use thereof
GB0111186D0 (en) Novel compounds
WO2007047447A3 (en) Diuretic-like compound analogs useful for regulation of central nervous system disorders
WO2002066672A3 (en) Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists
EP1032556A4 (en) Pharmaceutically active compounds and methods of use
GB0320320D0 (en) Novel compounds
MXPA02000330A (en) Neurotrophic pyrrolidines and piperidines, and related compositions and methods.
DE602004029671D1 (en) (1S, 5S) -3- (5,6-DICHLORO-3-PYRIDINYL) -3,6-DIAZABICYCLOÄ3.2.0ÜHEPTAN WITH ANALGETIC EFFICACY
WO2004016604A3 (en) Azabicyclic compounds are central nervous system active agents
NZ533358A (en) 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
WO2000006575A3 (en) Azabicyclic compounds
MXPA03001472A (en) Compounds for the treatment of addictive disorders.
WO2001007431A3 (en) Benzothiophene derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2495589

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005502054

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/001726

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003770235

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003770235

Country of ref document: EP